MX2023005031A - Compuesto degradante en un medicamento. - Google Patents

Compuesto degradante en un medicamento.

Info

Publication number
MX2023005031A
MX2023005031A MX2023005031A MX2023005031A MX2023005031A MX 2023005031 A MX2023005031 A MX 2023005031A MX 2023005031 A MX2023005031 A MX 2023005031A MX 2023005031 A MX2023005031 A MX 2023005031A MX 2023005031 A MX2023005031 A MX 2023005031A
Authority
MX
Mexico
Prior art keywords
medicament
brimonidine
carbachol
impurities
less
Prior art date
Application number
MX2023005031A
Other languages
English (en)
Inventor
Rhett Mead Schiffman
Bruce Alan Firestone
Original Assignee
Visus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visus Therapeutics Inc filed Critical Visus Therapeutics Inc
Publication of MX2023005031A publication Critical patent/MX2023005031A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente descripción se dirige a formulaciones oftalmológicas que comprenden carbacol, brimonidina, y menos del 5 % de una o más impurezas, procesos para preparar formulaciones oftalmológicas que comprenden carbacol, brimonidina, y menos del 5 % de una o más impurezas, y métodos para tratar la presbicia y otras afecciones oftalmológicas mediante la administración de formulaciones oftalmológicas que comprenden carbacol, brimonidina y menos de 5 % de una o más impurezas.
MX2023005031A 2020-11-02 2021-11-02 Compuesto degradante en un medicamento. MX2023005031A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063108720P 2020-11-02 2020-11-02
US202163162367P 2021-03-17 2021-03-17
US202163257024P 2021-10-18 2021-10-18
PCT/US2021/057720 WO2022094462A1 (en) 2020-11-02 2021-11-02 Degradant compound in a medicament

Publications (1)

Publication Number Publication Date
MX2023005031A true MX2023005031A (es) 2023-06-29

Family

ID=81383327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005031A MX2023005031A (es) 2020-11-02 2021-11-02 Compuesto degradante en un medicamento.

Country Status (12)

Country Link
US (2) US20230390284A1 (es)
EP (1) EP4236932A1 (es)
JP (1) JP2023548336A (es)
KR (1) KR20230104645A (es)
AU (1) AU2021369566A1 (es)
CA (1) CA3195784A1 (es)
CL (1) CL2023001258A1 (es)
CO (1) CO2023007133A2 (es)
CR (1) CR20230190A (es)
MX (1) MX2023005031A (es)
TW (1) TW202233170A (es)
WO (1) WO2022094462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117571883B (zh) * 2024-01-15 2024-03-19 四川智强医药科技开发有限公司 一种酒石酸溴莫尼定滴眼液的质量检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2016205068A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Storage stable compositions and methods for the treatment of refractive errors of the eye
CN108883102A (zh) * 2016-03-17 2018-11-23 远视眼治疗有限责任公司 用于治疗远视眼的组合物和方法
WO2019104191A1 (en) * 2017-11-21 2019-05-31 Sydnexis, Inc. Ophthalmic composition and delivery device thereof

Also Published As

Publication number Publication date
US20230390284A1 (en) 2023-12-07
CA3195784A1 (en) 2022-05-05
WO2022094462A1 (en) 2022-05-05
TW202233170A (zh) 2022-09-01
AU2021369566A1 (en) 2023-06-22
US20240100046A1 (en) 2024-03-28
KR20230104645A (ko) 2023-07-10
CR20230190A (es) 2023-09-06
JP2023548336A (ja) 2023-11-16
EP4236932A1 (en) 2023-09-06
CO2023007133A2 (es) 2023-06-20
CL2023001258A1 (es) 2023-12-22

Similar Documents

Publication Publication Date Title
EP4233861A3 (en) Compositions for treatment of essential tremor
ZA202109010B (en) Compounds and methods for the treatment of covid-19
TW201613588A (en) Ophthalmic composition
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
PH12014501955B1 (en) Diquafosol-containing eye drop
MX2022010483A (es) Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus.
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CO2023007133A2 (es) Compuesto degradante en un medicamento
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
ZA202108950B (en) Oxymetazoline compositions and methods for treating ocular disorders
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MY197721A (en) Composition and uses thereof
PH12020551620A1 (en) Compositions for preventing or treating dry eye
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
AU2020299145A8 (en) Compositions and methods for treating eye diseases
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
EA202092472A1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.